Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0JBFLL
ADC Name	WO2018098269A2 conjugate 61
Synonyms	WO2018098269A2_conjugate-61 Click to Show/Hide
Organization	Mersana Therapeutics, Inc.
Drug Status	Investigative
Indication	In total 3 Indication(s) Breast cancer [ICD11:2C60-2C65] Investigative Gastric cancer [ICD11:2B72] Investigative Ovarian cancer [ICD11:2C73] Investigative
Drug-to-Antibody Ratio	16.3
	3D MOL	2D MOL
Antibody Name	XMT-1535		Antibody Info
Antigen Name	Sodium-dependent phosphate transport protein 2B (SLC34A2)		Antigen Info
Payload Name	Undisclosed
Linker Name	WO2018098269A2_conjugate 61 linker
Conjugate Type	Random conjugation through reduced inter-chain cysteines.

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 45.7	%	CVCL_0465	Ovarian serous adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 45.70% (Day 32)	Positive HER2 expression (HER2+++/++)
Method Description	Female CB-17 SCID mice were inoculated subcutaneously with OVCAR-3 cells (n=10 for each group). Mice inoculated subcutaneously with NCI-N87 cells (n=10 for each group) after IV administration as a single dose (3 mg/kg) on day 1.
In Vivo Model	OVCAR-3 CDX model
In Vitro Model	Ovarian serous adenocarcinoma	OVCAR-3 cells		CVCL_0465

References

Ref 1	Peptide-containing linkers for antibody-drug conjugates.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.